Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...